Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research Apr 12, 2022
Revive Therapeutics May Seek FDA Approval To Amend Phase 3 Endpoints In Bucillamine Trial To A Symptoms Focus Apr 11, 2022
